Amneal Pharmaceuticals Inc at Barclays Global Healthcare Conference Transcript
Good afternoon. Continuing the session for the day. My name is Balaji from Barclays. And so we have with us today the management team from Amneal, including -- sorry, all right, there we go. So we have Rob Stewart, President and CEO; Paul Bisaro, Executive Chairman; and Todd Branning, SVP -- Senior Vice President and CFO. Gentlemen, thank you so much for taking the time out today. So the session will be in the form of a fireside chat, and our Q&As will be later on in the breakout session. And so before I launch into the sound of Q&As that we've discussed, Rob, would you like to kickstart off with some overview and comments.
Sure. First off, thank you for those attending here in person, as well as those that have dialed in via the webcast. I appreciate the time and the opportunity to meet with all of you. Summing up, 2018 was a transformational year for the company. We were starting with the Impax-Amneal deal
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
